Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideto Tamura

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cancer Biomarkers : Section a of Disease Markers|April 11, 2016
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromesSumiko Kobayashi, Yasunori Ueda, Yasuhito Nannya, et al.
International Journal of Hematology|July 9, 2017
Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in JapanAkio Saito, Atsushi Isoda, Masaru Kojima, et al.
Oncotarget|November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myelomaMariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Annals of Hematology|July 1, 2016
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' eraYutaka Tsukune, Makoto Sasaki, Takeshi Odajima, et al.
Molecular Cancer Research : MCR|January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple MyelomaMariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
International Journal of Hematology|November 25, 2024
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit studyTsuyoshi Muta, Yosuke Masamoto, Go Yamamoto, et al.
Blood|March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasoneYasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
Annals of Hematology|September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in JapanYuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
International Journal of Hematology|March 29, 2024
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021)Hirohiko Shibayama, Mitsuhiro Itagaki, Hiroshi Handa, et al.
Leukemia & Lymphoma|November 1, 2012
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromesYasunori Ueda, Chisato Mizutani, Yasuhito Nannya, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cancer Biomarkers : Section a of Disease Markers|April 11, 2016
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromesSumiko Kobayashi, Yasunori Ueda, Yasuhito Nannya, et al.
International Journal of Hematology|July 9, 2017
Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in JapanAkio Saito, Atsushi Isoda, Masaru Kojima, et al.
Oncotarget|November 10, 2018
Clinical impact of serum soluble SLAMF7 in multiple myelomaMariko Ishibashi, Saori Soeda, Makoto Sasaki, et al.
Annals of Hematology|July 1, 2016
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' eraYutaka Tsukune, Makoto Sasaki, Takeshi Odajima, et al.
Molecular Cancer Research : MCR|January 25, 2020
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple MyelomaMariko Ishibashi, Risa Takahashi, Asako Tsubota, et al.
International Journal of Hematology|November 25, 2024
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit studyTsuyoshi Muta, Yosuke Masamoto, Go Yamamoto, et al.
Blood|March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasoneYasunori Kogure, Hiroshi Handa, Yuta Ito, et al.
Annals of Hematology|September 11, 2023
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in JapanYuichi Horigome, Masaki Iino, Yoriko Harazaki, et al.
International Journal of Hematology|March 29, 2024
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021)Hirohiko Shibayama, Mitsuhiro Itagaki, Hiroshi Handa, et al.
Leukemia & Lymphoma|November 1, 2012
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromesYasunori Ueda, Chisato Mizutani, Yasuhito Nannya, et al.
Pageof 7